 | • レポートコード：MRC2Q12-18984 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、糖尿病治療薬の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に糖尿病治療薬のグローバル市場のxxx％を占める「インスリン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「1型糖尿病」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 糖尿病治療薬の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの糖尿病治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 糖尿病治療薬のグローバル主要プレイヤーには、Sanofi、AstraZeneca、Bayer、Biocon、Boehringer Ingelheim、Dongbao Pharmaceutical、Eli Lilly、Ganlee、Ginwa、Guangzhou Baiyun Mountain、Hisun Pharmacy、Hua Dong、Huadong Medicine、Jumpcan Pharmacy、KELUN、Merck & Co.、MSD、North China Pharmaceutical Group Corporation、Novartis、Novo Nordisk、Sanofi、SHIJIAZHUANG YILING PHARMACEUTICAL、Takeda、Taloph、Tianan Pharmaceutical、Tonghua DongBao、Wanbang Biopharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 糖尿病治療薬市場は、種類と用途によって区分されます。世界の糖尿病治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 インスリン、DPP-4、GLP-1、SGLT-2 【用途別セグメント】 1型糖尿病、2型糖尿病 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 糖尿病治療薬製品概要 - 種類別市場（インスリン、DPP-4、GLP-1、SGLT-2） - 用途別市場（1型糖尿病、2型糖尿病） - 調査の目的 ・エグゼクティブサマリー - 世界の糖尿病治療薬販売量予測2017-2028 - 世界の糖尿病治療薬売上予測2017-2028 - 糖尿病治療薬の地域別販売量 - 糖尿病治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別糖尿病治療薬販売量 - 主要メーカー別糖尿病治療薬売上 - 主要メーカー別糖尿病治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（インスリン、DPP-4、GLP-1、SGLT-2） - 糖尿病治療薬の種類別販売量 - 糖尿病治療薬の種類別売上 - 糖尿病治療薬の種類別価格 ・用途別市場規模（1型糖尿病、2型糖尿病） - 糖尿病治療薬の用途別販売量 - 糖尿病治療薬の用途別売上 - 糖尿病治療薬の用途別価格 ・北米市場 - 北米の糖尿病治療薬市場規模（種類別、用途別） - 主要国別の糖尿病治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの糖尿病治療薬市場規模（種類別、用途別） - 主要国別の糖尿病治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の糖尿病治療薬市場規模（種類別、用途別） - 主要国別の糖尿病治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の糖尿病治療薬市場規模（種類別、用途別） - 主要国別の糖尿病治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの糖尿病治療薬市場規模（種類別、用途別） - 主要国別の糖尿病治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Sanofi、AstraZeneca、Bayer、Biocon、Boehringer Ingelheim、Dongbao Pharmaceutical、Eli Lilly、Ganlee、Ginwa、Guangzhou Baiyun Mountain、Hisun Pharmacy、Hua Dong、Huadong Medicine、Jumpcan Pharmacy、KELUN、Merck & Co.、MSD、North China Pharmaceutical Group Corporation、Novartis、Novo Nordisk、Sanofi、SHIJIAZHUANG YILING PHARMACEUTICAL、Takeda、Taloph、Tianan Pharmaceutical、Tonghua DongBao、Wanbang Biopharmaceuticals ・産業チェーン及び販売チャネル分析 - 糖尿病治療薬の産業チェーン分析 - 糖尿病治療薬の原材料 - 糖尿病治療薬の生産プロセス - 糖尿病治療薬の販売及びマーケティング - 糖尿病治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 糖尿病治療薬の産業動向 - 糖尿病治療薬のマーケットドライバー - 糖尿病治療薬の課題 - 糖尿病治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Diabetes Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Diabetes Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Diabetes Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Diabetes Medicines include Sanofi, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Dongbao Pharmaceutical, Eli Lilly, Ganlee and Ginwa, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Diabetes Medicines manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Diabetes Medicines market. Further, it explains the major drivers and regional dynamics of the global Diabetes Medicines market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Sanofi
AstraZeneca
Bayer
Biocon
Boehringer Ingelheim
Dongbao Pharmaceutical
Eli Lilly
Ganlee
Ginwa
Guangzhou Baiyun Mountain
Hisun Pharmacy
Hua Dong
Huadong Medicine
Jumpcan Pharmacy
KELUN
Merck & Co.
MSD
North China Pharmaceutical Group Corporation
Novartis
Novo Nordisk
Sanofi
SHIJIAZHUANG YILING PHARMACEUTICAL
Takeda
Taloph
Tianan Pharmaceutical
Tonghua DongBao
Wanbang Biopharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Diabetes Medicines Segment by Type
Insulin
DPP-4
GLP-1
SGLT-2
Diabetes Medicines Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Diabetes Medicines market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Diabetes Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Diabetes Medicines, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Diabetes Medicines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diabetes Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Diabetes Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Diabetes Medicines sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Dongbao Pharmaceutical, Eli Lilly, Ganlee and Ginwa, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Diabetes Medicines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Diabetes Medicines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diabetes Medicines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Diabetes Medicines Product Introduction
1.2 Market by Type
1.2.1 Global Diabetes Medicines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Insulin
1.2.3 DPP-4
1.2.4 GLP-1
1.2.5 SGLT-2
1.3 Market by Application
1.3.1 Global Diabetes Medicines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diabetes Medicines Sales Estimates and Forecasts 2017-2028
2.2 Global Diabetes Medicines Revenue Estimates and Forecasts 2017-2028
2.3 Global Diabetes Medicines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diabetes Medicines Sales by Region
2.4.1 Global Diabetes Medicines Sales by Region (2017-2022)
2.4.2 Global Sales Diabetes Medicines by Region (2023-2028)
2.5 Global Diabetes Medicines Revenue by Region
2.5.1 Global Diabetes Medicines Revenue by Region (2017-2022)
2.5.2 Global Diabetes Medicines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diabetes Medicines Sales by Manufacturers
3.1.1 Global Top Diabetes Medicines Manufacturers by Sales (2017-2022)
3.1.2 Global Diabetes Medicines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diabetes Medicines in 2021
3.2 Global Diabetes Medicines Revenue by Manufacturers
3.2.1 Global Diabetes Medicines Revenue by Manufacturers (2017-2022)
3.2.2 Global Diabetes Medicines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diabetes Medicines Revenue in 2021
3.3 Global Diabetes Medicines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diabetes Medicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diabetes Medicines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diabetes Medicines Sales by Type
4.1.1 Global Diabetes Medicines Historical Sales by Type (2017-2022)
4.1.2 Global Diabetes Medicines Forecasted Sales by Type (2023-2028)
4.1.3 Global Diabetes Medicines Sales Market Share by Type (2017-2028)
4.2 Global Diabetes Medicines Revenue by Type
4.2.1 Global Diabetes Medicines Historical Revenue by Type (2017-2022)
4.2.2 Global Diabetes Medicines Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diabetes Medicines Revenue Market Share by Type (2017-2028)
4.3 Global Diabetes Medicines Price by Type
4.3.1 Global Diabetes Medicines Price by Type (2017-2022)
4.3.2 Global Diabetes Medicines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diabetes Medicines Sales by Application
5.1.1 Global Diabetes Medicines Historical Sales by Application (2017-2022)
5.1.2 Global Diabetes Medicines Forecasted Sales by Application (2023-2028)
5.1.3 Global Diabetes Medicines Sales Market Share by Application (2017-2028)
5.2 Global Diabetes Medicines Revenue by Application
5.2.1 Global Diabetes Medicines Historical Revenue by Application (2017-2022)
5.2.2 Global Diabetes Medicines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diabetes Medicines Revenue Market Share by Application (2017-2028)
5.3 Global Diabetes Medicines Price by Application
5.3.1 Global Diabetes Medicines Price by Application (2017-2022)
5.3.2 Global Diabetes Medicines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diabetes Medicines Market Size by Type
6.1.1 North America Diabetes Medicines Sales by Type (2017-2028)
6.1.2 North America Diabetes Medicines Revenue by Type (2017-2028)
6.2 North America Diabetes Medicines Market Size by Application
6.2.1 North America Diabetes Medicines Sales by Application (2017-2028)
6.2.2 North America Diabetes Medicines Revenue by Application (2017-2028)
6.3 North America Diabetes Medicines Market Size by Country
6.3.1 North America Diabetes Medicines Sales by Country (2017-2028)
6.3.2 North America Diabetes Medicines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Diabetes Medicines Market Size by Type
7.1.1 Europe Diabetes Medicines Sales by Type (2017-2028)
7.1.2 Europe Diabetes Medicines Revenue by Type (2017-2028)
7.2 Europe Diabetes Medicines Market Size by Application
7.2.1 Europe Diabetes Medicines Sales by Application (2017-2028)
7.2.2 Europe Diabetes Medicines Revenue by Application (2017-2028)
7.3 Europe Diabetes Medicines Market Size by Country
7.3.1 Europe Diabetes Medicines Sales by Country (2017-2028)
7.3.2 Europe Diabetes Medicines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diabetes Medicines Market Size by Type
8.1.1 Asia Pacific Diabetes Medicines Sales by Type (2017-2028)
8.1.2 Asia Pacific Diabetes Medicines Revenue by Type (2017-2028)
8.2 Asia Pacific Diabetes Medicines Market Size by Application
8.2.1 Asia Pacific Diabetes Medicines Sales by Application (2017-2028)
8.2.2 Asia Pacific Diabetes Medicines Revenue by Application (2017-2028)
8.3 Asia Pacific Diabetes Medicines Market Size by Region
8.3.1 Asia Pacific Diabetes Medicines Sales by Region (2017-2028)
8.3.2 Asia Pacific Diabetes Medicines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Diabetes Medicines Market Size by Type
9.1.1 Latin America Diabetes Medicines Sales by Type (2017-2028)
9.1.2 Latin America Diabetes Medicines Revenue by Type (2017-2028)
9.2 Latin America Diabetes Medicines Market Size by Application
9.2.1 Latin America Diabetes Medicines Sales by Application (2017-2028)
9.2.2 Latin America Diabetes Medicines Revenue by Application (2017-2028)
9.3 Latin America Diabetes Medicines Market Size by Country
9.3.1 Latin America Diabetes Medicines Sales by Country (2017-2028)
9.3.2 Latin America Diabetes Medicines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Diabetes Medicines Market Size by Type
10.1.1 Middle East and Africa Diabetes Medicines Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diabetes Medicines Revenue by Type (2017-2028)
10.2 Middle East and Africa Diabetes Medicines Market Size by Application
10.2.1 Middle East and Africa Diabetes Medicines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diabetes Medicines Revenue by Application (2017-2028)
10.3 Middle East and Africa Diabetes Medicines Market Size by Country
10.3.1 Middle East and Africa Diabetes Medicines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diabetes Medicines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AstraZeneca Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Overview
11.3.3 Bayer Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bayer Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bayer Recent Developments
11.4 Biocon
11.4.1 Biocon Corporation Information
11.4.2 Biocon Overview
11.4.3 Biocon Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Biocon Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Biocon Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Corporation Information
11.5.2 Boehringer Ingelheim Overview
11.5.3 Boehringer Ingelheim Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Boehringer Ingelheim Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Boehringer Ingelheim Recent Developments
11.6 Dongbao Pharmaceutical
11.6.1 Dongbao Pharmaceutical Corporation Information
11.6.2 Dongbao Pharmaceutical Overview
11.6.3 Dongbao Pharmaceutical Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Dongbao Pharmaceutical Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Dongbao Pharmaceutical Recent Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Corporation Information
11.7.2 Eli Lilly Overview
11.7.3 Eli Lilly Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Eli Lilly Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Eli Lilly Recent Developments
11.8 Ganlee
11.8.1 Ganlee Corporation Information
11.8.2 Ganlee Overview
11.8.3 Ganlee Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Ganlee Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Ganlee Recent Developments
11.9 Ginwa
11.9.1 Ginwa Corporation Information
11.9.2 Ginwa Overview
11.9.3 Ginwa Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Ginwa Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Ginwa Recent Developments
11.10 Guangzhou Baiyun Mountain
11.10.1 Guangzhou Baiyun Mountain Corporation Information
11.10.2 Guangzhou Baiyun Mountain Overview
11.10.3 Guangzhou Baiyun Mountain Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Guangzhou Baiyun Mountain Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Guangzhou Baiyun Mountain Recent Developments
11.11 Hisun Pharmacy
11.11.1 Hisun Pharmacy Corporation Information
11.11.2 Hisun Pharmacy Overview
11.11.3 Hisun Pharmacy Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Hisun Pharmacy Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Hisun Pharmacy Recent Developments
11.12 Hua Dong
11.12.1 Hua Dong Corporation Information
11.12.2 Hua Dong Overview
11.12.3 Hua Dong Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Hua Dong Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Hua Dong Recent Developments
11.13 Huadong Medicine
11.13.1 Huadong Medicine Corporation Information
11.13.2 Huadong Medicine Overview
11.13.3 Huadong Medicine Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Huadong Medicine Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Huadong Medicine Recent Developments
11.14 Jumpcan Pharmacy
11.14.1 Jumpcan Pharmacy Corporation Information
11.14.2 Jumpcan Pharmacy Overview
11.14.3 Jumpcan Pharmacy Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Jumpcan Pharmacy Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Jumpcan Pharmacy Recent Developments
11.15 KELUN
11.15.1 KELUN Corporation Information
11.15.2 KELUN Overview
11.15.3 KELUN Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 KELUN Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 KELUN Recent Developments
11.16 Merck & Co.
11.16.1 Merck & Co. Corporation Information
11.16.2 Merck & Co. Overview
11.16.3 Merck & Co. Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Merck & Co. Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Merck & Co. Recent Developments
11.17 MSD
11.17.1 MSD Corporation Information
11.17.2 MSD Overview
11.17.3 MSD Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 MSD Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 MSD Recent Developments
11.18 North China Pharmaceutical Group Corporation
11.18.1 North China Pharmaceutical Group Corporation Corporation Information
11.18.2 North China Pharmaceutical Group Corporation Overview
11.18.3 North China Pharmaceutical Group Corporation Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 North China Pharmaceutical Group Corporation Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 North China Pharmaceutical Group Corporation Recent Developments
11.19 Novartis
11.19.1 Novartis Corporation Information
11.19.2 Novartis Overview
11.19.3 Novartis Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Novartis Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Novartis Recent Developments
11.20 Novo Nordisk
11.20.1 Novo Nordisk Corporation Information
11.20.2 Novo Nordisk Overview
11.20.3 Novo Nordisk Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Novo Nordisk Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Novo Nordisk Recent Developments
11.21 Sanofi
11.21.1 Sanofi Corporation Information
11.21.2 Sanofi Overview
11.21.3 Sanofi Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Sanofi Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Sanofi Recent Developments
11.22 SHIJIAZHUANG YILING PHARMACEUTICAL
11.22.1 SHIJIAZHUANG YILING PHARMACEUTICAL Corporation Information
11.22.2 SHIJIAZHUANG YILING PHARMACEUTICAL Overview
11.22.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
11.23 Takeda
11.23.1 Takeda Corporation Information
11.23.2 Takeda Overview
11.23.3 Takeda Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Takeda Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Takeda Recent Developments
11.24 Taloph
11.24.1 Taloph Corporation Information
11.24.2 Taloph Overview
11.24.3 Taloph Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Taloph Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Taloph Recent Developments
11.25 Tianan Pharmaceutical
11.25.1 Tianan Pharmaceutical Corporation Information
11.25.2 Tianan Pharmaceutical Overview
11.25.3 Tianan Pharmaceutical Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Tianan Pharmaceutical Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Tianan Pharmaceutical Recent Developments
11.26 Tonghua DongBao
11.26.1 Tonghua DongBao Corporation Information
11.26.2 Tonghua DongBao Overview
11.26.3 Tonghua DongBao Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 Tonghua DongBao Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 Tonghua DongBao Recent Developments
11.27 Wanbang Biopharmaceuticals
11.27.1 Wanbang Biopharmaceuticals Corporation Information
11.27.2 Wanbang Biopharmaceuticals Overview
11.27.3 Wanbang Biopharmaceuticals Diabetes Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.27.4 Wanbang Biopharmaceuticals Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.27.5 Wanbang Biopharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diabetes Medicines Industry Chain Analysis
12.2 Diabetes Medicines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diabetes Medicines Production Mode & Process
12.4 Diabetes Medicines Sales and Marketing
12.4.1 Diabetes Medicines Sales Channels
12.4.2 Diabetes Medicines Distributors
12.5 Diabetes Medicines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diabetes Medicines Industry Trends
13.2 Diabetes Medicines Market Drivers
13.3 Diabetes Medicines Market Challenges
13.4 Diabetes Medicines Market Restraints
14 Key Findings in The Global Diabetes Medicines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Diabetes Medicines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Insulin
Table 3. Major Manufacturers of DPP-4
Table 4. Major Manufacturers of GLP-1
Table 5. Major Manufacturers of SGLT-2
Table 6. Global Diabetes Medicines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Diabetes Medicines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Diabetes Medicines Sales by Region (2017-2022) & (K Units)
Table 9. Global Diabetes Medicines Sales Market Share by Region (2017-2022)
Table 10. Global Diabetes Medicines Sales by Region (2023-2028) & (K Units)
Table 11. Global Diabetes Medicines Sales Market Share by Region (2023-2028)
Table 12. Global Diabetes Medicines Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Diabetes Medicines Revenue Market Share by Region (2017-2022)
Table 14. Global Diabetes Medicines Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Diabetes Medicines Revenue Market Share by Region (2023-2028)
Table 16. Global Diabetes Medicines Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Diabetes Medicines Sales Share by Manufacturers (2017-2022)
Table 18. Global Diabetes Medicines Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Diabetes Medicines Revenue Share by Manufacturers (2017-2022)
Table 20. Diabetes Medicines Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Diabetes Medicines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Diabetes Medicines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetes Medicines as of 2021)
Table 23. Diabetes Medicines Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Diabetes Medicines Product Offered
Table 25. Date of Manufacturers Enter into Diabetes Medicines Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 28. Global Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 29. Global Diabetes Medicines Sales Share by Type (2017-2022)
Table 30. Global Diabetes Medicines Sales Share by Type (2023-2028)
Table 31. Global Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Diabetes Medicines Revenue Share by Type (2017-2022)
Table 34. Global Diabetes Medicines Revenue Share by Type (2023-2028)
Table 35. Diabetes Medicines Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Diabetes Medicines Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 38. Global Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 39. Global Diabetes Medicines Sales Share by Application (2017-2022)
Table 40. Global Diabetes Medicines Sales Share by Application (2023-2028)
Table 41. Global Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Diabetes Medicines Revenue Share by Application (2017-2022)
Table 44. Global Diabetes Medicines Revenue Share by Application (2023-2028)
Table 45. Diabetes Medicines Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Diabetes Medicines Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 48. North America Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 49. North America Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 52. North America Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 53. North America Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Diabetes Medicines Sales by Country (2017-2022) & (K Units)
Table 56. North America Diabetes Medicines Sales by Country (2023-2028) & (K Units)
Table 57. North America Diabetes Medicines Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Diabetes Medicines Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 60. Europe Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 61. Europe Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 64. Europe Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 65. Europe Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Diabetes Medicines Sales by Country (2017-2022) & (K Units)
Table 68. Europe Diabetes Medicines Sales by Country (2023-2028) & (K Units)
Table 69. Europe Diabetes Medicines Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Diabetes Medicines Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Diabetes Medicines Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Diabetes Medicines Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Diabetes Medicines Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Diabetes Medicines Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Diabetes Medicines Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Diabetes Medicines Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Diabetes Medicines Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Diabetes Medicines Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Diabetes Medicines Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Diabetes Medicines Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Diabetes Medicines Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Diabetes Medicines Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Diabetes Medicines Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Diabetes Medicines Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Diabetes Medicines Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Diabetes Medicines Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Diabetes Medicines Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Diabetes Medicines Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Diabetes Medicines Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Diabetes Medicines Revenue by Country (2023-2028) & (US$ Million)
Table 107. Sanofi Corporation Information
Table 108. Sanofi Description and Major Businesses
Table 109. Sanofi Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Sanofi Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sanofi Recent Developments
Table 112. AstraZeneca Corporation Information
Table 113. AstraZeneca Description and Major Businesses
Table 114. AstraZeneca Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. AstraZeneca Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. AstraZeneca Recent Developments
Table 117. Bayer Corporation Information
Table 118. Bayer Description and Major Businesses
Table 119. Bayer Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Bayer Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Bayer Recent Developments
Table 122. Biocon Corporation Information
Table 123. Biocon Description and Major Businesses
Table 124. Biocon Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Biocon Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Biocon Recent Developments
Table 127. Boehringer Ingelheim Corporation Information
Table 128. Boehringer Ingelheim Description and Major Businesses
Table 129. Boehringer Ingelheim Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Boehringer Ingelheim Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Boehringer Ingelheim Recent Developments
Table 132. Dongbao Pharmaceutical Corporation Information
Table 133. Dongbao Pharmaceutical Description and Major Businesses
Table 134. Dongbao Pharmaceutical Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Dongbao Pharmaceutical Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Dongbao Pharmaceutical Recent Developments
Table 137. Eli Lilly Corporation Information
Table 138. Eli Lilly Description and Major Businesses
Table 139. Eli Lilly Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Eli Lilly Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Eli Lilly Recent Developments
Table 142. Ganlee Corporation Information
Table 143. Ganlee Description and Major Businesses
Table 144. Ganlee Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Ganlee Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Ganlee Recent Developments
Table 147. Ginwa Corporation Information
Table 148. Ginwa Description and Major Businesses
Table 149. Ginwa Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Ginwa Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Ginwa Recent Developments
Table 152. Guangzhou Baiyun Mountain Corporation Information
Table 153. Guangzhou Baiyun Mountain Description and Major Businesses
Table 154. Guangzhou Baiyun Mountain Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Guangzhou Baiyun Mountain Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Guangzhou Baiyun Mountain Recent Developments
Table 157. Hisun Pharmacy Corporation Information
Table 158. Hisun Pharmacy Description and Major Businesses
Table 159. Hisun Pharmacy Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Hisun Pharmacy Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Hisun Pharmacy Recent Developments
Table 162. Hua Dong Corporation Information
Table 163. Hua Dong Description and Major Businesses
Table 164. Hua Dong Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. Hua Dong Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Hua Dong Recent Developments
Table 167. Huadong Medicine Corporation Information
Table 168. Huadong Medicine Description and Major Businesses
Table 169. Huadong Medicine Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 170. Huadong Medicine Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Huadong Medicine Recent Developments
Table 172. Jumpcan Pharmacy Corporation Information
Table 173. Jumpcan Pharmacy Description and Major Businesses
Table 174. Jumpcan Pharmacy Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 175. Jumpcan Pharmacy Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Jumpcan Pharmacy Recent Developments
Table 177. KELUN Corporation Information
Table 178. KELUN Description and Major Businesses
Table 179. KELUN Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 180. KELUN Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. KELUN Recent Developments
Table 182. Merck & Co. Corporation Information
Table 183. Merck & Co. Description and Major Businesses
Table 184. Merck & Co. Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 185. Merck & Co. Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Merck & Co. Recent Developments
Table 187. MSD Corporation Information
Table 188. MSD Description and Major Businesses
Table 189. MSD Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 190. MSD Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. MSD Recent Developments
Table 192. North China Pharmaceutical Group Corporation Corporation Information
Table 193. North China Pharmaceutical Group Corporation Description and Major Businesses
Table 194. North China Pharmaceutical Group Corporation Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 195. North China Pharmaceutical Group Corporation Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 196. North China Pharmaceutical Group Corporation Recent Developments
Table 197. Novartis Corporation Information
Table 198. Novartis Description and Major Businesses
Table 199. Novartis Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 200. Novartis Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 201. Novartis Recent Developments
Table 202. Novo Nordisk Corporation Information
Table 203. Novo Nordisk Description and Major Businesses
Table 204. Novo Nordisk Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 205. Novo Nordisk Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 206. Novo Nordisk Recent Developments
Table 207. Sanofi Corporation Information
Table 208. Sanofi Description and Major Businesses
Table 209. Sanofi Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 210. Sanofi Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 211. Sanofi Recent Developments
Table 212. SHIJIAZHUANG YILING PHARMACEUTICAL Corporation Information
Table 213. SHIJIAZHUANG YILING PHARMACEUTICAL Description and Major Businesses
Table 214. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 215. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 216. SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
Table 217. Takeda Corporation Information
Table 218. Takeda Description and Major Businesses
Table 219. Takeda Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 220. Takeda Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 221. Takeda Recent Developments
Table 222. Taloph Corporation Information
Table 223. Taloph Description and Major Businesses
Table 224. Taloph Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 225. Taloph Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 226. Taloph Recent Developments
Table 227. Tianan Pharmaceutical Corporation Information
Table 228. Tianan Pharmaceutical Description and Major Businesses
Table 229. Tianan Pharmaceutical Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 230. Tianan Pharmaceutical Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 231. Tianan Pharmaceutical Recent Developments
Table 232. Tonghua DongBao Corporation Information
Table 233. Tonghua DongBao Description and Major Businesses
Table 234. Tonghua DongBao Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 235. Tonghua DongBao Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 236. Tonghua DongBao Recent Developments
Table 237. Wanbang Biopharmaceuticals Corporation Information
Table 238. Wanbang Biopharmaceuticals Description and Major Businesses
Table 239. Wanbang Biopharmaceuticals Diabetes Medicines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 240. Wanbang Biopharmaceuticals Diabetes Medicines Product Model Numbers, Pictures, Descriptions and Specifications
Table 241. Wanbang Biopharmaceuticals Recent Developments
Table 242. Key Raw Materials Lists
Table 243. Raw Materials Key Suppliers Lists
Table 244. Diabetes Medicines Distributors List
Table 245. Diabetes Medicines Customers List
Table 246. Diabetes Medicines Market Trends
Table 247. Diabetes Medicines Market Drivers
Table 248. Diabetes Medicines Market Challenges
Table 249. Diabetes Medicines Market Restraints
Table 250. Research Programs/Design for This Report
Table 251. Key Data Information from Secondary Sources
Table 252. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetes Medicines Product Picture
Figure 2. Global Diabetes Medicines Market Share by Type in 2021 & 2028
Figure 3. Insulin Product Picture
Figure 4. DPP-4 Product Picture
Figure 5. GLP-1 Product Picture
Figure 6. SGLT-2 Product Picture
Figure 7. Global Diabetes Medicines Market Share by Application in 2021 & 2028
Figure 8. Type 1 Diabetes
Figure 9. Type 2 Diabetes
Figure 10. Diabetes Medicines Report Years Considered
Figure 11. Global Diabetes Medicines Sales 2017-2028 (K Units)
Figure 12. Global Diabetes Medicines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Diabetes Medicines Revenue 2017-2028 (US$ Million)
Figure 14. Global Diabetes Medicines Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Diabetes Medicines Sales Market Share by Region (2017-2022)
Figure 16. Global Diabetes Medicines Sales Market Share by Region (2023-2028)
Figure 17. North America Diabetes Medicines Sales YoY (2017-2028) & (K Units)
Figure 18. North America Diabetes Medicines Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Diabetes Medicines Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Diabetes Medicines Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Diabetes Medicines Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Diabetes Medicines Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Diabetes Medicines Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Diabetes Medicines Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Diabetes Medicines Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Diabetes Medicines Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Diabetes Medicines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Diabetes Medicines in the World: Market Share by Diabetes Medicines Revenue in 2021
Figure 29. Global Diabetes Medicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 31. Global Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 32. Global Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 33. Global Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 34. North America Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 35. North America Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 36. North America Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 37. North America Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 38. North America Diabetes Medicines Sales Share by Country (2017-2028)
Figure 39. North America Diabetes Medicines Revenue Share by Country (2017-2028)
Figure 40. United States Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 43. Europe Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 44. Europe Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 45. Europe Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 46. Europe Diabetes Medicines Sales Share by Country (2017-2028)
Figure 47. Europe Diabetes Medicines Revenue Share by Country (2017-2028)
Figure 48. Germany Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 49. France Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Diabetes Medicines Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Diabetes Medicines Revenue Share by Region (2017-2028)
Figure 59. China Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 62. India Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 69. Latin America Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 71. Latin America Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Diabetes Medicines Sales Share by Country (2017-2028)
Figure 73. Latin America Diabetes Medicines Revenue Share by Country (2017-2028)
Figure 74. Mexico Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Diabetes Medicines Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Diabetes Medicines Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Diabetes Medicines Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Diabetes Medicines Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Diabetes Medicines Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Diabetes Medicines Revenue Share by Country (2017-2028)
Figure 84. Turkey Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Diabetes Medicines Revenue (2017-2028) & (US$ Million)
Figure 87. Diabetes Medicines Value Chain
Figure 88. Diabetes Medicines Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed